Loading...

TYRA TYRA BIOSCIENCES INC US FDA Inspections 8-K Filing

TYR

TYR

TYRA BIOSCIENCES INC

(TYRA)

2024 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Financial Results

Director Resignation

Equity Exchange

Financial Results Announcement

Annual Meeting and Liabilit...

Financial Results Announcement

Appointment of Directors

Earnings Reports

Private Placement

FDA Designation for TYRA-30...

Initiation of SURF201 Phase...

Earnings Reports

Amended and Restated Bylaws

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Incentive Plan Adoption and...

External Links:

Tyra Biosciences announced that the FDA has granted Rare Pediatric Disease Designation to TYRA-300 for the treatment of achondroplasia, potentially making them eligible for a Priority Review Voucher.

AI Assistant

TYRA BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.